EMA Grants Orphan Drug Designation to Rafael ...
Rafael Pharmaceuticals' CPI-613 (devimistat) received EMA orphan drug designation for treating refractory/relapsed Burkitt’s lymphoma, a rare NHL variant. Devimistat targets tumor cell survival mechanisms, marking its third EMA ODD. It also holds seven FDA ODDs, offering hope for patients with limited treatment options.
Reference News
EMA Grants Orphan Drug Designation to Rafael ...
Rafael Pharmaceuticals' CPI-613 (devimistat) received EMA orphan drug designation for treating refractory/relapsed Burkitt’s lymphoma, a rare NHL variant. Devimistat targets tumor cell survival mechanisms, marking its third EMA ODD. It also holds seven FDA ODDs, offering hope for patients with limited treatment options.